2019
Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men
Chandrasekar T, Gross L, Gomella L, Hegarty S, Leong J, Giri V. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology 2019, 3: 291-297. PMID: 31278035, DOI: 10.1016/j.euo.2019.06.010.Peer-Reviewed Original ResearchConceptsHereditary cancer syndromesProstate cancerCancer syndromesFamily historyGermline mutationsExact testHereditary breastGenetic testingAfrican AmericansPCa family historyAfrican American patientsOvarian cancer syndromeCascade genetic testingFisher's exact testHereditary prostate cancerBRCA mutationsLynch syndromeOvarian cancerSyndromeCancerCascade testingDiverse cohortAA participantsSpectrum of genesFHx
2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal Of Clinical Oncology 2017, 36: jco.2017.74.117. PMID: 29236593, PMCID: PMC6075860, DOI: 10.1200/jco.2017.74.1173.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancerGenetic testingMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAggressive prostate cancerProstate cancer riskGenetic counselingMultidisciplinary consensus statementDNA mismatch repair genesExpert consensus conferenceFamilial prostate cancerHereditary prostate cancerClinical genetic testingMismatch repair genesMetastatic settingPCa managementLynch syndromeOvarian cancerBRCA2 mutationsConsensus statementFamily historyCancer riskHeterogeneous diseaseConsensus conferenceComprehensive genetic evaluation
2016
How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.
Giri V, Gross L, Gomella L, Hyatt C. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer. Canadian Journal Of Urology 2016, 23: 8247-53. PMID: 27085833.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancer patientsProstate cancerCancer patientsGenetic counselingProstate cancer risk assessmentGenetic testing guidelinesInherited prostate cancerHereditary cancer syndromesCancer risk assessmentProstate cancer predispositionFamily historyUrologic communityCancer syndromesCancerGenetic testingPatientsTesting guidelinesGenetic mutationsCounselingCancer predispositionUrologistsCurrent knowledgeSubstantial heritable componentGenetic contributionProviders
2013
Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer
Handorf E, Crumpler N, Gross L, Giri V. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal Of Genetic Counseling 2013, 23: 371-376. PMID: 24310616, PMCID: PMC4028414, DOI: 10.1007/s10897-013-9672-5.Peer-Reviewed Original ResearchConceptsHOXB13 G84E mutationProstate cancerG84E mutationFamily historyProstate cancer screening programsCancer screening programsProstate cancer screeningProstate cancer riskHigh-risk menMen ages 35HOXB13 G84ECancer screeningExact binomial confidence intervalsMutation carriersScreening programAge 35Cancer riskClinical utilityUnaffected menPrevalence estimatesGenetic testingPrevalenceCancerConfidence intervalsGenetic counseling
2009
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsy
2008
Substantial family history of prostate cancer in black men recruited for prostate cancer screening
Mastalski K, Coups E, Ruth K, Raysor S, Giri V. Substantial family history of prostate cancer in black men recruited for prostate cancer screening. Cancer 2008, 113: 2559-2564. PMID: 18816608, PMCID: PMC2626163, DOI: 10.1002/cncr.23862.Peer-Reviewed Original ResearchConceptsFH of PCaProstate Cancer Risk Assessment ProgramNational Health Interview SurveyProstate cancerFamily historyBlack menCancer Risk Assessment ProgramMore first-degree relativesSelf-reported family historyMore family historyProstate cancer screeningHigh-risk menMen ages 35First-degree relativesHealth Interview SurveyAge-matched sampleSuboptimal screeningCancer screeningBreast cancerScreening programAge 35Colon cancerPCa screeningRisk assessment programCancer